Chemours (NYSE: CC) Securities Class Action Lawsuit Over Opteon Demand, December 7, 2026 Lead Plaintiff Deadline for Investors Who Bought Between February 20 and August 4, 2026

A putative securities class action filed on October 8, 2026, in the U.S. District Court for the District of Delaware accuses The Chemours Company and two senior executives of misleading investors about demand for Opteon refrigerants and the reliability of the company’s 2026 outlook. Investors who bought Chemours securities between February 20, 2026 and August 4, 2026 have until December 7, 2026 to ask the court to appoint them lead plaintiff.

This is not a settlement. No class has been certified, no settlement has been announced, and there is no claim form to file. The allegations are unproven, and a law firm’s notice inviting investors to get in touch is not a finding of fraud or a promise of payment.

Quick Facts: Chemours (CC) Securities Class Action

Detail	Information
Company	The Chemours Company (NYSE: CC), Wilmington, Delaware
Case	Darcy v. The Chemours Company, et al., No. 1:26-cv-01299
Court	U.S. District Court for the District of Delaware
Filed	October 8, 2026
Defendants named in investor notices	Chemours, President and CEO Denise Dignam, CFO Shane Hostetter
Proposed class period	February 20, 2026 through August 4, 2026, inclusive
Core allegations	Overstated Opteon aftermarket demand, undisclosed channel oversupply, unreliable 2026 guidance
Laws cited	Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and SEC Rule 10b-5
Lead plaintiff motion deadline	December 7, 2026
Class certified	No
Settlement or claim form	None

What Does the Chemours Securities Lawsuit Allege About Opteon Demand?

According to the complaint as described in investor notices from Pomerantz LLP, Robbins LLP, Gainey McKenna & Egleston and Schall, Brown & Schwartz LLP, the defendants failed to disclose that:

1. They had materially overstated aftermarket demand for Chemours’ Opteon products.
2. Demand was decreasing because Chemours had oversold Opteon in the preceding fiscal year.
3. As a result, the company’s financial guidance for 2026 was unreliable.
4. Therefore, the company’s public statements were materially false and misleading throughout the class period.

The complaint’s theory is a channel-fill problem. A manufacturer can show strong sales when distributors stock up ahead of a product transition. If distributors then sell down that stock instead of reordering, later demand drops. That drop is not fraud by itself. Plaintiffs must show that the statements made during the class period were materially false or misleading and that the defendants had the required state of mind.

This case is also separate from Chemours’ environmental PFAS litigation, and from an earlier securities class action over a different class period (October 1, 2023 to February 28, 2024).

What Did Chemours Disclose on August 4, 2026?

Chemours released its second-quarter 2026 results on August 4, 2026, after the market closed. As described in the company’s release and in the complaint:

• Net sales were about $1.591 billion, compared with $1.615 billion a year earlier.
• The company reported a net loss attributable to Chemours of $274 million, compared with a $380 million net loss in the second quarter of 2025.
• Adjusted EBITDA was $247 million, compared with $260 million.
• Chemours attributed part of the sales decline to lower aftermarket Opteon refrigerant volumes. It said the second quarter of 2025 had been lifted by elevated demand from the initial stocking of products during the U.S. transition under the AIM Act.
• Full-year 2026 adjusted EBITDA guidance was lowered from $800 million to $900 million down to $775 million to $825 million.

On the earnings call, management said the initial channel fill led aftermarket customers to build extra inventory and left the channel oversupplied heading into 2026. According to investor notices quoting the call, management also said roughly $65 million of aftermarket sales in the second and third quarters was tied to the earlier channel fill.

Investor notices report that Chemours shares fell $3.34, about 18.63%, to close at $14.59 on August 5, 2026.

These disclosures document Chemours’ reported results. Whether any earlier statement was legally misleading is for the court to decide.

What Securities Laws Apply to the Chemours Class Action?

Section 10(b) and SEC Rule 10b-5

Section 10(b), 15 U.S.C. § 78j(b), and 17 C.F.R. § 240.10b-5 prohibit fraud in connection with buying or selling securities. A private plaintiff generally must prove:

• a material misrepresentation or omission,
• scienter (intent or extreme recklessness),
• a connection with the purchase or sale of a security,
• reliance,
• economic loss, and
• loss causation.

Several Supreme Court decisions shape how these elements work:

• Basic Inc. v. Levinson, 485 U.S. 224 (1988): investors in an efficient market can rely on the “fraud-on-the-market” presumption, which defendants may rebut, including with evidence of no price impact (Halliburton Co. v. Erica P. John Fund, 573 U.S. 258 (2014)).
• Dura Pharmaceuticals, Inc. v. Broudo, 544 U.S. 336 (2005): paying an inflated price is not enough. Plaintiffs must plead and prove that the misstatement caused an actual loss.
• Tellabs, Inc. v. Makor Issues & Rights, Ltd., 551 U.S. 308 (2007): the inference of scienter must be at least as compelling as any competing innocent inference.
• Macquarie Infrastructure Corp. v. Moab Partners, L.P., 601 U.S. 257 (2024): a pure omission, unlike a misleading half-truth, is not actionable under Rule 10b-5(b). That matters for claims that Chemours “failed to disclose” inventory levels.

Section 20(a): control-person liability

15 U.S.C. § 78t(a) can make a person who controls a primary violator jointly liable, subject to defenses. It is how plaintiffs usually reach executives such as a CEO and CFO. It requires a primary violation first.

The Private Securities Litigation Reform Act (PSLRA)

The PSLRA, codified mainly at 15 U.S.C. § 78u-4, sets the procedures for this case:

• Notice and the 60-day window. The first plaintiff must publish notice within 20 days of filing, and any class member has 60 days from that notice to move for lead plaintiff status (§ 78u-4(a)(3)(A)). That window produces the December 7 date.
• Lead plaintiff presumption. The court presumes the most adequate plaintiff is the person or group with the largest financial interest in the relief that otherwise meets the requirements of Federal Rule of Civil Procedure 23 (§ 78u-4(a)(3)(B)).
• Heightened pleading. The complaint must specify each misleading statement and why it was misleading, and must plead facts giving a strong inference of scienter (§ 78u-4(b)(1) and (b)(2)).
• Discovery stay. Discovery is stayed while a motion to dismiss is pending (§ 78u-4(b)(3)(B)).
• 90-day look-back. Damages are capped by the difference between the purchase price and the mean trading price during the 90 days after the corrective information is disclosed (§ 78u-4(e)).
• Safe harbor for forward-looking statements, 15 U.S.C. § 78u-5. Guidance is forward-looking. Defendants will likely argue it was protected by cautionary language or made without actual knowledge it was false. This will probably be central to any motion to dismiss because the complaint says the 2026 guidance was unreliable.

Securities fraud claims also face a limitations period of two years after discovery and five years after the violation (28 U.S.C. § 1658(b)). Those are not a concern for this early filing.

Who Is in the Proposed Chemours Class, and Do You Have to Become Lead Plaintiff?

The proposed class is everyone, other than the defendants, who purchased or otherwise acquired Chemours securities from February 20, 2026 through August 4, 2026, inclusive, and was damaged. The court may narrow or change that definition, and it has not certified any class.

You do not need to be lead plaintiff to be part of the class. Investors who do nothing generally remain absent class members and, if a class is certified and a settlement or judgment is later approved, would receive court-approved notice and a chance to submit a claim. Being a class member does not guarantee a payment.

The lead plaintiff directs the litigation on behalf of everyone, helps select lead counsel and is typically the investor or group with the largest financial loss. Seeking that role carries duties and is not a way to register for a payment.

What Is the December 7, 2026 Deadline for Chemours Investors?

December 7, 2026 is the deadline to file a motion asking the court to appoint you lead plaintiff. It is not a deadline to file a settlement claim, because there is no settlement. If you want to seek lead plaintiff status, talk to a securities lawyer well before that date. Lawyers usually need your trade records to calculate your loss.

How Does the PSLRA Process Work After the Deadline?

1. Lead plaintiff and lead counsel are appointed. Competing motions are common.
2. An amended or consolidated complaint is often filed after appointment.
3. Defendants move to dismiss. Most securities complaints face this challenge on pleading, scienter, loss causation and the forward-looking safe harbor.
4. Discovery and class certification follow only if the claims survive.
5. Settlement or trial. Many cases that survive dismissal settle, and the court must approve any class settlement after notice, with a chance to object.

None of these steps is guaranteed.

What Should Chemours Investors Do Now?

• Keep brokerage statements and trade confirmations for February 20 through August 4, 2026, plus any later sales.
• Decide whether you want to seek lead plaintiff status or monitor as a class member.
• Check the docket for No. 1:26-cv-01299 on PACER.
• Be careful with unsolicited offers or sites that promise a guaranteed recovery. Law firm notices are advertisements, not court notices.
• Do not assume you lost money because of the alleged fraud. An investor who sold before the August 4 disclosure may have no recoverable loss.

For another example of how a proposed securities class action differs from a settlement with a claims process, see GPGI Securities Class Action, What the $113.9 Million Q2 EBITDA Results Mean for Investors.

Is There a Chemours Securities Class Action Settlement?

No. As of October 11, 2026, the case is at the complaint stage. There is no settlement amount, administrator or claim deadline. If one comes, the court-approved notice will explain who qualifies and how to claim.

Timeline: Chemours Securities Class Action

Date	Event
February 20, 2026	Proposed class period begins
August 4, 2026	Chemours reports Q2 2026 results after the close and cuts full-year adjusted EBITDA guidance; class period ends
August 5, 2026	Shares reportedly fall about 18.63% to $14.59
October 8, 2026	Complaint filed in the District of Delaware, No. 1:26-cv-01299
October 9 to 10, 2026	Law firms publish PSLRA notices
December 7, 2026	Lead plaintiff motion deadline

Frequently Asked Questions About the Chemours (CC) Securities Class Action

Is there a securities class action against The Chemours Company?

Yes. A putative class action, No. 1:26-cv-01299, was filed October 8, 2026 in the District of Delaware.

What is the Chemours class period?

February 20, 2026 through August 4, 2026, inclusive.

What is the Chemours lead plaintiff deadline?

December 7, 2026.

What does the Chemours lawsuit allege?

That Chemours and two executives overstated aftermarket demand for Opteon, did not disclose that oversupply from the prior year was depressing demand, and issued unreliable 2026 guidance. These allegations have not been proven.

Who is named as a defendant?

The Chemours Company, Denise Dignam and Shane Hostetter, according to investor notices.

Do I have to be lead plaintiff to recover money?

No. Class members who do not seek the role may take part in a later recovery if one occurs.

Is there a Chemours settlement or claim form?

No.

Does the stock drop prove fraud?

No. Under Dura Pharmaceuticals v. Broudo, plaintiffs must still prove the misstatement caused the loss.

Is this related to Chemours’ PFAS lawsuits?

No. It concerns what investors were told about Opteon demand and guidance.

Can I be in the class if I sold before August 4, 2026?

You may have no recoverable loss from the alleged fraud, because the reported price drop followed the August 4 disclosure. The court will decide the final class definition.

Sources and Verification Notes

1. Pomerantz LLP, class action filing announcement (docket 26-cv-01299, class period and December 7, 2026 deadline), October 10, 2026: https://www.pr-inside.com/pomerantz-llp-announces-class-action-filing-against-the-chemours-company-r5232138.htm
2. Gainey McKenna & Egleston, GlobeNewswire, October 9, 2026: https://www.globenewswire.com/news-release/2026/10/09/3378274/10782/en/gainey-mckenna-egleston-announces-a-class-action-lawsuit-has-been-filed-against-the-chemours-company-cc.html
3. Robbins LLP, Business Wire investor alert and case page (allegations and call excerpts): https://robbinsllp.com/the-chemours-company-3/
4. Schall, Brown & Schwartz LLP, Business Wire, October 10, 2026: https://www.financialcontent.com/article/bizwire-2026-10-10-cc-investors-have-opportunity-to-lead-the-chemours-company-securities-fraud-lawsuit-with-sbs-law
5. Chemours second-quarter 2026 earnings release and Form 8-K, August 4, 2026: https://investors.chemours.com/news-releases/news-release-details/chemours-company-reports-second-quarter-results
6. Law cited: 15 U.S.C. §§ 78j(b), 78t(a), 78u-4, 78u-5; 17 C.F.R. § 240.10b-5; 28 U.S.C. § 1658(b); Fed. R. Civ. P. 23; Basic, Halliburton II, Dura, Tellabs, Macquarie.

Disclaimer: This article is general information, not legal or investment advice. Allegations are unproven.

Researched and written by Israr Ahmad, legal content researcher and founder of AllAboutLawyer.com. All facts verified against the investor notices of Pomerantz LLP, Robbins LLP, Gainey McKenna & Egleston and Schall, Brown & Schwartz LLP, as of October 11, 2026. Last Updated: October 11, 2026.